A Menke1, P Muntner, J M Fernández-Real, E Guallar. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Abstract
BACKGROUND AND AIMS: Elevated iron biomarkers are associated with diabetes and other cardiometabolic abnormalities in the general population. It is unclear whether they are associated with an increased risk of all-cause or cause-specific mortality. The purpose of the current analysis was to evaluate the association of ferritin and transferrin saturation levels with all-cause, cardiovascular, and cancer mortality in the general US adult population. METHODS AND RESULTS: A prospective cohort study was conducted with 12,258 adults participating in the Third National Health and Nutrition Examination Survey (NHANES III), a nationally representative sample of the US population. Study participants were recruited in 1988-1994 and followed through December 31, 2006 for all-cause, cardiovascular disease, and cancer mortality. The multivariable-adjusted hazard ratios (95% confidence interval) for all-cause mortality comparing the fourth versus the second quartiles of ferritin and transferrin saturation were 1.09 (0.82-1.44; p-trend across quartiles = 0.92) and 1.08 (0.82-1.43; p-trend across quartiles = 0.62), respectively, for men, 1.43 (0.63-3.23; p-trend across quartiles = 0.31) and 1.48 (0.70-3.11; p-trend across quartiles = 0.60), respectively, for premenopausal women, and 1.03 (0.79-1.34; p-trend across quartiles = 0.95) and 1.17 (0.92-1.49; p-trend across quartiles = 0.63), respectively, for postmenopausal women. Quartile of ferritin and transferrin saturation also showed no association between biomarkers of iron status and mortality. CONCLUSIONS: In a large nationally representative sample of US adults, within the spectrum of normal iron metabolism, ferritin and transferrin saturation were not associated with risk of mortality among people who were not taking iron supplements and did not have a baseline history of cardiovascular disease or cancer.
BACKGROUND AND AIMS: Elevated iron biomarkers are associated with diabetes and other cardiometabolic abnormalities in the general population. It is unclear whether they are associated with an increased risk of all-cause or cause-specific mortality. The purpose of the current analysis was to evaluate the association of ferritin and transferrin saturation levels with all-cause, cardiovascular, and cancer mortality in the general US adult population. METHODS AND RESULTS: A prospective cohort study was conducted with 12,258 adults participating in the Third National Health and Nutrition Examination Survey (NHANES III), a nationally representative sample of the US population. Study participants were recruited in 1988-1994 and followed through December 31, 2006 for all-cause, cardiovascular disease, and cancer mortality. The multivariable-adjusted hazard ratios (95% confidence interval) for all-cause mortality comparing the fourth versus the second quartiles of ferritin and transferrin saturation were 1.09 (0.82-1.44; p-trend across quartiles = 0.92) and 1.08 (0.82-1.43; p-trend across quartiles = 0.62), respectively, for men, 1.43 (0.63-3.23; p-trend across quartiles = 0.31) and 1.48 (0.70-3.11; p-trend across quartiles = 0.60), respectively, for premenopausal women, and 1.03 (0.79-1.34; p-trend across quartiles = 0.95) and 1.17 (0.92-1.49; p-trend across quartiles = 0.63), respectively, for postmenopausal women. Quartile of ferritin and transferrin saturation also showed no association between biomarkers of iron status and mortality. CONCLUSIONS: In a large nationally representative sample of US adults, within the spectrum of normal iron metabolism, ferritin and transferrin saturation were not associated with risk of mortality among people who were not taking iron supplements and did not have a baseline history of cardiovascular disease or cancer.
Authors: Neil A Zakai; Ronit Katz; Calvin Hirsch; Michael G Shlipak; Paulo H M Chaves; Anne B Newman; Mary Cushman Journal: Arch Intern Med Date: 2005-10-24
Authors: Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: Leo R Zacharski; Bruce K Chow; Paula S Howes; Galina Shamayeva; John A Baron; Ronald L Dalman; David J Malenka; C Keith Ozaki; Philip W Lavori Journal: JAMA Date: 2007-02-14 Impact factor: 56.272
Authors: Daphne L van der A; Maroeska M Rovers; Diederick E Grobbee; Joannes J M Marx; Jill Waalen; Christina Ellervik; Børge G Nordestgaard; John K Olynyk; Peter R Mills; James Shepherd; Bernard Grandchamp; Jolanda M A Boer; Calogero Caruso; Marcello Arca; Beat J Meyer; Yvonne T van der Schouw Journal: Circ Cardiovasc Genet Date: 2008-10
Authors: Motoi Kobayashi; Tomohiro Suhara; Yuichi Baba; Nicholas K Kawasaki; Jason K Higa; Takashi Matsui Journal: Curr Drug Targets Date: 2018 Impact factor: 3.465
Authors: An Pan; Qi Sun; Adam M Bernstein; Matthias B Schulze; JoAnn E Manson; Meir J Stampfer; Walter C Willett; Frank B Hu Journal: Arch Intern Med Date: 2012-03-12
Authors: Keir E J Philip; Ahmed S Sadaka; Michael I Polkey; Nicholas S Hopkinson; Andrew Steptoe; Daisy Fancourt Journal: Br J Haematol Date: 2020-02-18 Impact factor: 8.615
Authors: Arch G Mainous; Vanessa A Diaz; Michele E Knoll; Mary M Hulihan; Althea M Grant; Robert U Wright Journal: J Am Geriatr Soc Date: 2012-12-03 Impact factor: 5.562